(6-chloro-5-fluoro-1H-benzoimidazol-2-yl)-piperazin-1-yl-methanone | 673486-89-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (6-chloro-5-fluoro-1H-benzoimidazol-2-yl)-piperazin-1-yl-methanone
• 英文别名: (5-chloro-6-fluoro-1H-benzimidazol-2-yl)-piperazin-1-ylmethanone
• CAS: 673486-89-0
• 化学式: C₁₂H₁₂ClFN₄O
• 分子量: 282.705
• InChiKey: NRTDQBHBNUHMIL-UHFFFAOYSA-N

物化性质

• 沸点：
  486.7±55.0 °C(Predicted)
• 密度：
  1.469±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  19
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  61
• 氢给体数：
  2
• 氢受体数：
  4

文献信息

• Heterocyclic compounds
  申请人：——

  公开号：US20040058934A1

  公开（公告）日：2004-03-25

  Certain thienopyrrolyl and furanopyrrolyl compounds are disclosed as useful to treat or prevent disorders and conditions mediated by the histamine H 4 receptor, including allergic rhinitis.

  某些噻吩吡咯基和呋喃吡咯基化合物被揭示为治疗或预防由组胺H4受体介导的疾病和病症，包括过敏性鼻炎的有用药物。
• [EN] HETEROCYCLIC COMPOUNDS<br/>[FR] COMPOSES HETEROCYCLIQUES
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2004022060A2

  公开（公告）日：2004-03-18

  (1H-Benzoimidazol-2-YL)-(Piperazinyl)-Methanone derivatives of formula (I) and related compounds as histamine H4-receptor antagonists for the treatment of inflammatory and allergic disorders (I) wherein B and B1 are C or up to one of B and B1 may be N; Y is O, S or NR2, where R2 is H or C1-4alkyl; Z is O or S; R8 is H and R9 is (a), where R10 Is H or C1-4alkyl, or R8 and R9 are taken together with their N of attachment to form (b); n is 1 or 2; m is 1 or 2; n + m is 2 or 3; other substituents as defined in claim 1.

  (1H-苯并咪唑-2-基)-(哌嗪基)-甲酰胺类化合物(I)及其相关化合物，作为组胺H4受体拮抗剂用于治疗炎症性和过敏性疾病。 其中，B和B₁是C，或者B和B₁中至多一个为N；Y是O、S或NR₂，其中R₂是H或C₁₋₄烷基；Z是O或S；R₈是H，且R₉是(a)，其中R₁₀是H或C₁₋₄烷基，或者R₈和R₉与它们的连接N原子一起形成(b)；n是1或2；m是1或2；n + m是2或3；其他取代基如权利要求1所述。
• HETEROCYCLIC COMPOUNDS
  申请人：JANSSEN PHARMACEUTICA N.V.

  公开号：EP1545532A2

  公开（公告）日：2005-06-29
• Combination Histamine H1R and H4R Antagonist Therapy for Treating Pruritus
  申请人：Dunford Paul J.

  公开号：US20090069343A1

  公开（公告）日：2009-03-12

  Patients suffering from pruritus or itch may be effectively treated by administering a centrally acting histamine H1 receptor antagonist (e.g., diphenhydramine, triprolidine, hydroxyzine, pyrilamine, promethazine, or chlorpheniramine) and a histamine H4 receptor antagonist (e.g., 5-chloro-1H-indol-2-yl)-(4-methyl-piperazin-1-yl)-methanone).
• US7504426B2
  申请人：——

  公开号：US7504426B2

  公开（公告）日：2009-03-17